Statements (54)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:chemical_compound
|
| gptkbp:bfsLayer |
5
|
| gptkbp:bfsParent |
gptkb:Clavinova
|
| gptkbp:activities |
Dopamine receptor antagonist
Serotonin receptor agonist |
| gptkbp:class |
thiazole derivatives
piperazine derivatives |
| gptkbp:clinical_trial |
gptkb:Europe
gptkb:Asia gptkb:United_States moderate Phase II |
| gptkbp:collaborations |
gptkb:Pharma_Corp
Health Innovations Inc. Bio Tech Solutions |
| gptkbp:composed_of |
multi-step synthesis
|
| gptkbp:discovered_by |
high-throughput screening
|
| gptkbp:dissolved |
soluble in DMSO
slightly soluble in water |
| gptkbp:excretion |
urine
|
| https://www.w3.org/2000/01/rdf-schema#label |
CLP-585
|
| gptkbp:ingredients |
C20 H24 N2 O2 S
|
| gptkbp:invention |
patented
|
| gptkbp:lifespan |
approximately 12 hours
|
| gptkbp:market |
not yet marketed
|
| gptkbp:metabolism |
liver
|
| gptkbp:previous_name |
(2 S)-2-(4-(4-(2-(4-(trifluoromethyl)phenyl)piperazin-1-yl)butyl)phenyl)thiazol-2-yl) N-(4-fluorophenyl)propanamide
|
| gptkbp:produced_by |
gptkb:legal_case
|
| gptkbp:products |
CLP-1001
CLP-2000 CLP-290 CLP-3000 CLP-4000 |
| gptkbp:research_areas |
gptkb:XYZ_University
neuroscience psychiatry ABC Research Center antipsychotic DEF Institute of Medicine |
| gptkbp:safety_features |
generally well tolerated
|
| gptkbp:side_effect |
nausea
drowsiness constipation dry mouth weight gain |
| gptkbp:targets |
schizophrenia
bipolar disorder major depressive disorder Dopamine receptor D2 Serotonin receptor 5-H T1 A |
| gptkbp:type_of |
123456-78-9
|
| gptkbp:weight |
356.48 g/mol
|
| gptkbp:year_created |
gptkb:2003
gptkb:2005 |